Candidate antibodies were initially conjugated to MMAE payloads and evaluated for their ability to inhibit the growth of the BT-474, an ER+, progesterone receptor (PR)-, HER2+ breast cancer cell line. The gene discussed is PGR; the disease is breast cancer.